Difference between revisions of "CT Acquisition Protocol Groundwork"
| (7 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
Q. Should we propose two protocols 1) for high resolution; and (2) for world-wide trials in patients with late stage disease? | Q. Should we propose two protocols 1) for high resolution; and (2) for world-wide trials in patients with late stage disease? | ||
| + | * Or maybe we should define a several protocols with different "quality" scores | ||
| + | ** Early stage disease is a different beast than later stage disease in terms of how they appear, how they should be imaged and how successful different kinds of image processing and measurement | ||
| + | ''<Lets start with a blend of NLST and ACRIN 6678 (see below)>'' | ||
| + | ''<Should seriously consider "raising the bar" to take a little more advantage of newer scanners>'' | ||
| + | |||
| + | ===Factors and Issues=== | ||
| + | |||
| + | The potential advantages of setting the parameter bar high: | ||
| + | * better images | ||
| + | * lower dose | ||
| + | * ... | ||
| + | |||
| + | need to be balanced against the costs: | ||
| + | * fewer scanners will be able to meet the requirements | ||
| + | * fewer sites will be able to follow the profile/participate in a related trial | ||
| + | * prior studies and baseline data that followed the "lower bar" may no longer be comparable | ||
==Related Work== | ==Related Work== | ||
| Line 16: | Line 32: | ||
** Table provides comparable acq. parameters for different scanners (16-18 models) | ** Table provides comparable acq. parameters for different scanners (16-18 models) | ||
** Maps corresponding differences in terms and header details | ** Maps corresponding differences in terms and header details | ||
| − | * ACRIN 6678 is a | + | * [http://www.acrin.org/TabID/162/Default.aspx ACRIN 6678] is a diagnostic-oriented (less concern on dose) that also does similar work |
** Does not appear to have the comprehensive table of parameters that NLST does | ** Does not appear to have the comprehensive table of parameters that NLST does | ||
| + | ** FOV (Field of View) is an issue because of interactions between the needs of CT and PET | ||
===Reviewing Acquisition Protocols=== | ===Reviewing Acquisition Protocols=== | ||
Latest revision as of 21:52, 15 December 2008
Goal:
Proposed Protocol
Q. Should we propose two protocols 1) for high resolution; and (2) for world-wide trials in patients with late stage disease?
- Or maybe we should define a several protocols with different "quality" scores
- Early stage disease is a different beast than later stage disease in terms of how they appear, how they should be imaged and how successful different kinds of image processing and measurement
<Lets start with a blend of NLST and ACRIN 6678 (see below)>
<Should seriously consider "raising the bar" to take a little more advantage of newer scanners>
Factors and Issues
The potential advantages of setting the parameter bar high:
- better images
- lower dose
- ...
need to be balanced against the costs:
- fewer scanners will be able to meet the requirements
- fewer sites will be able to follow the profile/participate in a related trial
- prior studies and baseline data that followed the "lower bar" may no longer be comparable
Related Work
Defining Acquisition Protocols
ACRIN has defined a number of protocols for CT-based clinical trials.
- CT Lung Specific protocols and QA procedures are discussed in work done for the ACRIN National Lung Screening Trial
- Table provides comparable acq. parameters for different scanners (16-18 models)
- Maps corresponding differences in terms and header details
- ACRIN 6678 is a diagnostic-oriented (less concern on dose) that also does similar work
- Does not appear to have the comprehensive table of parameters that NLST does
- FOV (Field of View) is an issue because of interactions between the needs of CT and PET
Reviewing Acquisition Protocols
UPICT is preparing a process for proposing/reviewing protocols and has access to experts for reviews.
It would likely be beneficial to review our proposed protocols with them.
Storing/Transfering Acquisition Protocols
DICOM is working on a format for encoding acquisition protocols as DICOM objects which can be stored/retrieved.
Field Testing Acquisition Protocols
Q. Should we broadcast our proposed protocols for general use in pharma trials that are starting up now, before we complete our profiles and groundwork?